On 15 October 2014, orphan designation (EU/3/14/1342) was granted by the European Commission to S-cubed Limited, United Kingdom, for glucagon for the treatment of congenital hyperinsulinism.
The sponsorship was transferred to S-cubed Pharmaceutical Services ApS, Denmark, in January 2019.
|Disease / condition||
Treatment of congenital hyperinsulinism
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;